These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 35316106)

  • 1. Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).
    Markati T; Fisher G; Ramdas S; Servais L
    Expert Opin Investig Drugs; 2022 May; 31(5):451-461. PubMed ID: 35316106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risdiplam: A Review in Spinal Muscular Atrophy.
    Paik J
    CNS Drugs; 2022 Apr; 36(4):401-410. PubMed ID: 35284988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.
    Poirier A; Weetall M; Heinig K; Bucheli F; Schoenlein K; Alsenz J; Bassett S; Ullah M; Senn C; Ratni H; Naryshkin N; Paushkin S; Mueller L
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00447. PubMed ID: 30519476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Risdiplam for the treatment of spinal muscular atrophy].
    Vlodavets DV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence: Risdiplam in a patient with spinal muscular atrophy type I with a novel splicing mutation and one SMN2 copy.
    Ma K; Zhang K; Chen D; Wang C; Abdalla M; Zhang H; Tian R; Liu Y; Song L; Zhang X; Liu F; Liu G; Wang D
    Hum Mol Genet; 2024 Jun; 33(13):1120-1130. PubMed ID: 38520738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).
    Ratni H; Ebeling M; Baird J; Bendels S; Bylund J; Chen KS; Denk N; Feng Z; Green L; Guerard M; Jablonski P; Jacobsen B; Khwaja O; Kletzl H; Ko CP; Kustermann S; Marquet A; Metzger F; Mueller B; Naryshkin NA; Paushkin SV; Pinard E; Poirier A; Reutlinger M; Weetall M; Zeller A; Zhao X; Mueller L
    J Med Chem; 2018 Aug; 61(15):6501-6517. PubMed ID: 30044619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
    Sturm S; Günther A; Jaber B; Jordan P; Al Kotbi N; Parkar N; Cleary Y; Frances N; Bergauer T; Heinig K; Kletzl H; Marquet A; Ratni H; Poirier A; Müller L; Czech C; Khwaja O
    Br J Clin Pharmacol; 2019 Jan; 85(1):181-193. PubMed ID: 30302786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain.
    Cornell N; Childs AM; Wraige E; Munot P; Ambegaonkar G; Chow G; Hughes I; Illingworth M; Majumdar A; Marini-Bettolo C; Parasuraman D; Spinty S; Willis T; Scoto M; Baranello G;
    J Neuromuscul Dis; 2024; 11(2):361-368. PubMed ID: 38189761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy.
    Ando S; Suzuki S; Okubo S; Ohuchi K; Takahashi K; Nakamura S; Shimazawa M; Fuji K; Hara H
    Sci Rep; 2020 Oct; 10(1):17472. PubMed ID: 33060681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advance in Disease Modifying Therapies for Spinal Muscular Atrophy.
    Tsai LK; Ting CH; Liu YT; Hsiao CT; Weng WC;
    Acta Neurol Taiwan; 2024 Sep; 33(3)():81-88. PubMed ID: 39363429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
    Kletzl H; Marquet A; Günther A; Tang W; Heuberger J; Groeneveld GJ; Birkhoff W; Mercuri E; Lochmüller H; Wood C; Fischer D; Gerlach I; Heinig K; Bugawan T; Dziadek S; Kinch R; Czech C; Khwaja O
    Neuromuscul Disord; 2019 Jan; 29(1):21-29. PubMed ID: 30553700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experience with the use of risdiplam in a familial case of spinal muscular atrophy 5q in patients with a homozygous deletion of the SMN1 gene and the same copy number of the SMN2 gene].
    Novikova ES
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(5):138-141. PubMed ID: 38884441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims Analysis.
    Pineda ED; To TM; Dickendesher TL; Shapouri S; Iannaccone ST
    Adv Ther; 2024 Jun; 41(6):2446-2459. PubMed ID: 38709394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
    Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
    Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risdiplam: First Approval.
    Dhillon S
    Drugs; 2020 Nov; 80(17):1853-1858. PubMed ID: 33044711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).
    Oskoui M; Day JW; Deconinck N; Mazzone ES; Nascimento A; Saito K; Vuillerot C; Baranello G; Goemans N; Kirschner J; Kostera-Pruszczyk A; Servais L; Papp G; Gorni K; Kletzl H; Martin C; McIver T; Scalco RS; Staunton H; Yeung WY; Fontoura P; Mercuri E;
    J Neurol; 2023 May; 270(5):2531-2546. PubMed ID: 36735057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities.
    Servais L; Baranello G; Scoto M; Daron A; Oskoui M
    Expert Opin Investig Drugs; 2021 May; 30(5):519-527. PubMed ID: 33749510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.
    Feng Z; Ling KK; Zhao X; Zhou C; Karp G; Welch EM; Naryshkin N; Ratni H; Chen KS; Metzger F; Paushkin S; Weetall M; Ko CP
    Hum Mol Genet; 2016 Mar; 25(5):964-75. PubMed ID: 26758873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment.
    Mercuri E; Baranello G; Boespflug-Tanguy O; De Waele L; Goemans N; Kirschner J; Masson R; Mazzone ES; Pechmann A; Pera MC; Vuillerot C; Bader-Weder S; Gerber M; Gorni K; Hoffart J; Kletzl H; Martin C; McIver T; Scalco RS; Yeung WY; Servais L;
    Eur J Neurol; 2023 Jul; 30(7):1945-1956. PubMed ID: 35837793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam.
    Chiriboga CA; Bruno C; Duong T; Fischer D; Mercuri E; Kirschner J; Kostera-Pruszczyk A; Jaber B; Gorni K; Kletzl H; Carruthers I; Martin C; Scalco RS; Fontoura P; Muntoni F;
    J Neurol; 2024 Aug; 271(8):4871-4884. PubMed ID: 38733387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.